Document:

EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

CONSENT, WAIVER AND AMENDMENT NO. 12 TO CREDIT AGREEMENT 

This CONSENT, WAIVER AND AMENDMENT NO. 12 TO CREDIT AGREEMENT (this “Amendment”), dated as of December
[    ], 2015, among USMD HOLDINGS, INC., a Delaware corporation “Holdings”), UROLOGY ASSOCIATES OF NORTH TEXAS, P.L.L.C., Texas professional limited liability company, USMD INC., a Texas corporation, IMPEL
MANAGEMENT SERVICES, L.L.C., a Texas limited liability company, IMPEL CONSULTING EXPERTS, L.L.C., a Texas limited liability company, MAT-RX DEVELOPMENT, L.L.C., a Texas limited liability company, USMD OF ARLINGTON GP, L.L.C., a Texas limited
liability company, US LITHOTRIPSY, L.P., a Texas limited partnership (“US Lithotripsy”), USMD CANCER TREATMENT CENTERS, L.L.C., a Texas limited liability company, USMD CANCER TREATMENT CENTERS GP, L.L.C., Texas limited liability
company, USMD PPM, LLC, a Texas limited liability company, USMD DIAGNOSTIC SERVICES, LLC, a Texas limited liability company, MAT-RX FORT WORTH GP, L.L.C., a Texas limited liability company, USMD ADMINISTRATIVE SERVICES, L.L.C., Texas limited
liability company, USGP, LLC, a Texas limited liability company (“USGP”), LITHO GP, LLC, a Texas limited liability company (“Litho GP”), METRO I STONE MANAGEMENT, LTD., a Texas limited partnership (“Metro
I”), USMD AFFILIATED SERVICES, a Texas not for profit corporation, MEDICAL CLINIC OF NORTH TEXAS PLLC, a Texas professional limited liability company, and USMD CTC (MO), LLC, a Missouri limited liability company (individually a
“Borrower” and collectively, the “Borrowers”), the undersigned Lenders (as defined below), and SOUTHWEST BANK, a Texas state bank, as administrative agent for the Lenders (the “Administrative
Agent”). 
 PRELIMINARY STATEMENTS: 

(1) The Borrowers, the lenders party thereto (the “Lenders”), and the Administrative Agent are parties to that certain Credit
Agreement dated as of August 31, 2012, as amended by that certain Amendment No. 1 to Credit Agreement dated as of February 28, 2013, as further amended by that certain Amendment No. 2 to Credit Agreement dated as of
September 13, 2013, as further amended by that certain Amendment No. 3 to Credit Agreement dated as of February 25, 2014, as further amended by that certain Waiver and Amendment No. 4 to Credit Agreement dated as of
April 14, 2014, as further amended by that certain Amendment No. 5 to Credit Agreement dated as of September 23, 2014, as further amended by that certain Amendment No. 6 to Credit Agreement and Amendment No. 1 to Guarantee
and Collateral Agreement, dated as of December 22, 2014, as further amended by that certain Amendment No. 7 to Credit Agreement, dated as of March 13, 2015, as further amended by that certain Amendment No. 8 to Credit Agreement
dated as of April 29, 2015, as further amended by that certain Amendment No. 9 to Credit Agreement and Amendment No. 2 to Guarantee and Collateral Agreement dated as of August 11, 2015, as further amended by that certain
Amendment No. 10 to Credit Agreement, dated as of September 18, 2015, as amended by that certain Amendment No. 11 to Credit Agreement, dated as of November 13, 2015 (as so amended, the “Credit Agreement”). 

(2) USMD Inc., USGP, US Lithotripsy. and United Medical Systems (DE), Inc. (the “Purchaser”) have entered into a Securities
Purchase Agreement, dated as of December [    ], 2015 (the “Securities Purchase Agreement”), pursuant to which USMD Inc. has agreed to sell to the Purchaser, and the Purchaser has agreed to purchase from USMD
Inc., the Purchased Securities (as defined in the Securities Purchase Agreement) (the “Sale”). 

 (3) The Borrowers have requested that the Lenders and the Administrative Agent consent to the
Sale and that the Credit Agreement be amended in the manner provided for in this Amendment. 
 NOW, THEREFORE, in consideration of the
premises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound hereby, hereby agree as follows: 

SECTION 1. Defined Terms. Unless otherwise defined herein, capitalized terms which are defined in the Credit Agreement are used
herein as therein defined. 
 SECTION 2. Consent. 

(a) Notwithstanding Sections 6.05 and 7.01(l) of the Credit Agreement, the Lender and the Administrative Agent hereby consent to (i) the
Sale, (ii) the transfer by Metro I of its 27.694% limited partnership interest in Dallas Stone Management, L.P., a Texas limited partnership, to US Lithotripsy in accordance with Section 4.4(e) of the Securities Purchase Agreement, and
(iii) the transfer by US Lithotripsy of its 60% limited partnership interest in Metro I to USMD Inc. 
 (b) Notwithstanding
Section 6.09(a) of the Credit Agreement and Section 2 of the Subordination Agreement, the Lender and the Administrative Agent hereby consent to the payment in full of the Subordinated Debt owed to John House and Paul Thompson with Net Cash
Proceeds from the Sale. 
 SECTION 3. Release of USGP, Litho GP, US Lithotripsy and Metro I. 

(a) Effective as of the Effective Time (as defined in the Securities Purchase Agreement), the Lender and the Administrative Agent hereby
(i) release USGP, Litho GP, US Lithotripsy and Metro I (collectively, the “Released Borrowers”) from all of their respective obligations under the Loan Documents, except for their obligations under this Amendment,
(ii) release all Liens granted pursuant to the Loan Documents on the assets of the Released Borrowers, and (iii) release all Liens granted pursuant to the Loan Documents on the Equity Interests of the Released Borrowers. 

(b) Effective as of the Effective Time, each of the Released Borrowers will no longer be a Borrower under the Credit Agreement or a guarantor
or a grantor under the Guarantee and Collateral Agreement. 
 (c) Effective as of the Effective Time, the Released Parties and their
designees are authorized to file the UCC financing statement amendments attached hereto as Annex B. 
 (d) After the occurrence of
the Effective Time, the Administrative Agent agrees, at the expense of the Released Borrowers, to execute and deliver to the Released Borrowers, from time to time, such further releases, Uniform Commercial Code termination statements, and other
documents as may be reasonably requested by the Released Borrowers to carry out the provisions and purposes of Sections 3(a) and 3(b) of this Amendment. 

  
 2 

 SECTION 4. Waiver. The Lender and the Administrative Agent agree to waive any
mandatory prepayment of the Tranche A Term Loans required pursuant to Section 2.09(b) of the Credit Agreement solely as a result of the Sale. 

SECTION 5. Amendment to Credit Agreement. The Credit Agreement is hereby amended as follows: 

(a) Paragraph (b) of the definition of “Change of Control” contained in Section 1.01 of the Credit
Agreement is hereby amended and restated in its entirety as follows: 
 “(b) during any period of 12 consecutive months,
a majority of the members of the board of directors or other equivalent governing body of Holdings cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, or
(ii) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or
equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or
nomination at least a majority of that board or equivalent governing body; or” 
 (b) Section 6.02(c) of the Credit
Agreement is hereby amended and restated in its entirety to read as follows: 
 “(c) Guarantee Obligations incurred by
the Borrowers (i) in respect of any Indebtedness of any of the Borrowers otherwise permitted by this Section 6.02, (ii) with respect to the CTC Entities, in an aggregate amount, for all such entities, not to exceed at any time
outstanding $2,000,000 in excess of the amounts then owing under the guarantee of existing Indebtedness by CTC Entities identified on Schedule 6.02(d) to the Credit Agreement (provided that, for purposes of the calculations under this
Section 6.02(c), the amounts used as the amounts then owing under the guarantee of existing Indebtedness by CTC Entities identified on Schedule 6.02(d), shall reduce as such guaranteed Indebtedness is paid or reduced [and not thereafter
increase after such reduction] and shall in no event exceed $1,086,715), and (iii) with respect to the Hospital Entities, in an aggregate amount, for all such entities, not to exceed at any time outstanding $3,000,000 in excess of the amounts
then owing under the guarantees of existing Indebtedness by Hospital Entities identified on Schedule 6.02(d) to the Credit Agreement (provided that, for purposes of the calculations under this Section 6.02(c), the amounts used as the amounts
then owing under the guarantees of existing Indebtedness by Hospital Entities identified on Schedule 6.02(d), shall reduce as such guaranteed Indebtedness is paid or reduced [and not thereafter increase after such reduction] and shall in no event
exceed the portion of the Indebtedness guaranteed by Hospital Entities under Schedule 6.02(d), paragraphs 1 and 2);”. 

  
 3 

 (c) Exhibit B (Form of Compliance Certificate) of the Credit Agreement is
hereby amended and restated in its entirety in the form of Annex C hereto. 
 (d) Schedule 6.08(g) of the
Credit Agreement is hereby amended and restated in its entirety in the form of Annex D hereto. 
 SECTION 6. Conditions
to Effectiveness. This Amendment shall become effective when the Administrative Agent shall have received counterparts of this Amendment duly executed by all of the Borrowers. Notwithstanding the effectiveness of this Amendment,
(i) Sections 2(a) and 3 hereof shall only become effective when the conditions precedent set forth in paragraphs (a), (b) and (c) below have been satisfied and (ii) Sections 2(b), 4 and 5 hereof shall only become effective when
all of the following conditions precedent have been satisfied: 
 (a) Officers’ Certificate. The Administrative
Agent shall have received a certificate of the Borrower Representative, on behalf of each Borrower, in form and substance reasonably satisfactory to the Administrative Agent, certifying (i) that resolutions of the board of directors, board of
managers or other appropriate governing body of each Borrower, previously certified and delivered to the Administrative Agent, authorize the execution, delivery and performance by such Borrower of this Amendment and each of the other documents
required to be executed by such Borrower hereunder and such resolutions are in full force and effect and have not been amended or modified, (ii) the officers of each Borrower (A) who are authorized to sign this Amendment and the other
documents required hereby and to which such Borrower is a party and (B) who will, until replaced by another officer or officers duly authorized for that purpose, act as its representative for the purposes of signing documents and giving notices
and other communications in connection with this Amendment, the Credit Agreement and the other Loan Documents, (iii) specimen signatures of such authorized officers, and (iv) that the Organizational Documents of each Borrower most recently
certified and delivered to the Administrative Agent, are in full force effect and have not been amended or modified. The Administrative Agent and the Lenders may conclusively rely on such certificate until the Administrative Agent receives notice in
writing from the Borrower Representative. 
 (b) Securities Purchase Agreement and Related Documents. The
Administrative Agent shall have received a correct and complete copy of the fully executed Securities Purchase Agreement (including all exhibits, schedules and amendments thereto) and correct and complete copies of the Indemnity Escrow Agreement (as
defined in the Securities Purchase Agreement) and all other documents executed and delivered pursuant to the Securities Purchase Agreement, certified by the Borrower Representative. 

(c) Fees and Expenses. The Administrative Agent shall have received evidence that the Borrowers shall have paid to the
Administrative Agent all out-of-pocket fees and expenses of the Administrative Agent incurred in connection with this Amendment and the transactions contemplated hereby (including, to the extent invoiced, the out-of-pocket fees, disbursements and
charges of counsel to the Administrative Agent). 
 (d) Other Documents. The Administrative Agent shall have received
such other certificates, documents and agreements as the Administrative Agent may reasonably request. 

  
 4 

 SECTION 7. Representations and Warranties of the Borrowers. To induce the
Administrative Agent and the Lenders to enter into this Amendment, each of the Borrowers hereby represents and warrants to the Administrative Agent and all of the Lenders as of the date hereof that: 

(a) Existence; etc. Each Borrower is duly organized, validly existing and in good standing under the laws of the
jurisdiction indicated in the preamble of this Amendment. 
 (b) No Legal Bar. Each Borrower has the power, authority,
and legal right to execute, deliver and perform its obligations under this Amendment and each other document or instrument required to be executed and delivered by it hereunder. The execution, delivery and performance by each Borrower of this
Amendment and each other document or instrument required to be executed and delivered by such Borrower hereunder have been duly authorized by all necessary organizational action and do not and will not (i) contravene or violate any of the
Organizational Documents of such Borrower, (ii) violate any Requirement of Law, (iii) violate any Contractual Obligation binding on or affecting such Borrower or any of its assets, (iv) violate any order, injunction, writ or decree of
any Governmental Authority or any arbitral award to which such Borrower or its property is subject or (v) result in, or require, the creation or imposition of any mortgage, deed of trust, pledge, Lien, security interest or other charge,
encumbrance or preferential arrangement of any nature (other than pursuant to the Security Documents) upon or with respect to any of the properties now owned or hereafter acquired by such Borrower. 

(c) Approvals. No consent or authorization of, approval by, notice to, filing with or other act by or in respect of, any
Governmental Authority or any other Person is required in connection with the execution, delivery and performance of this Amendment by any of the Borrowers. 

(d) Enforceable Obligations. This Amendment has been duly executed and delivered by each Borrower. This Amendment
constitutes a legal, valid and binding obligation of each Borrower enforceable against each Borrower in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws
affecting the enforcement of creditors’ rights generally and general equitable principles. 
 (e) Security
Documents. Except as provided in Section 3(a) above, the Security Documents constitute valid and perfected security interests and liens in and to the Collateral covered thereby with the priority required thereunder and secure the payment
and performance of the Secured Obligations, and all action required to perfect fully such security interests and liens has been taken and completed, and the execution, delivery and performance of this Amendment do not adversely affect any such
security interests and liens or the perfection or priority thereof. 
 (f) No Default. No Default or Event of Default
has occurred and is continuing. 
 (g) Representations and Warranties. The representations and warranties made by each
of the Borrowers in the Credit Agreement and the other Loan Documents are true and 

  
 5 

 
correct in all material respects on and as of the date hereof (except to the extent such representations and warranties relate, by their terms, to a specific earlier date, in which case they
shall be true and correct on and as of such earlier date). 
 (h) Guarantee Obligations in Respect of Released Borrowers
and Lithotripsy Entities. Annex C hereto contains a correct and complete list of all Guarantee Obligations of the Borrowers (other than the Released Borrowers) with respect to Indebtedness (other than the Secured Obligations), leases and
other obligations of the Released Borrowers. 
 SECTION 8. RELEASE; COVENANT NOT TO SUE; ACKNOWLEDGMENT. (a) EACH BORROWER
(COLLECTIVELY, THE “RELEASING PARTIES”) HEREBY ABSOLUTELY AND UNCONDITIONALLY RELEASES AND FOREVER DISCHARGES THE ADMINISTRATIVE AGENT AND EACH LENDER, AND ANY AND ALL RELATED PARTIES OF ANY OF THE ADMINISTRATIVE AGENT AND EACH
LENDER (EACH A “RELEASED PARTY”), FROM ANY AND ALL CLAIMS, DEMANDS OR CAUSES OF ACTION OF ANY KIND, NATURE OR DESCRIPTION RELATING TO OR ARISING OUT OF OR IN CONNECTION WITH OR AS A RESULT OF ANY OF THE OBLIGATIONS, THE CREDIT
AGREEMENT, THIS AMENDMENT, OR ANY OF THE OTHER LOAN DOCUMENTS, WHETHER ARISING IN LAW OR EQUITY OR UPON CONTRACT OR TORT OR UNDER ANY STATE OR FEDERAL LAW OR OTHERWISE, WHICH EACH RELEASING PARTY HAS HAD, NOW HAS OR HAS MADE CLAIM TO HAVE AGAINST
ANY RELEASED PARTY FOR OR BY REASON OF ANY ACT, OMISSION, MATTER, CAUSE OR THING WHATSOEVER ARISING FROM THE BEGINNING OF TIME TO AND INCLUDING THE DATE OF THIS AMENDMENT, WHETHER SUCH CLAIMS, DEMANDS AND CAUSES OF ACTION ARE MATURED OR UNMATURED OR
KNOWN OR UNKNOWN. IT IS THE INTENTION OF EACH RELEASING PARTY IN PROVIDING THIS RELEASE THAT THE SAME SHALL BE EFFECTIVE AS A BAR TO EACH AND EVERY CLAIM, DEMAND AND CAUSE OF ACTION SPECIFIED. EACH RELEASING PARTY ACKNOWLEDGES THAT IT MAY HEREAFTER
DISCOVER FACTS DIFFERENT FROM OR IN ADDITION TO THOSE NOW KNOWN OR BELIEVED TO BE TRUE WITH RESPECT TO SUCH CLAIMS, DEMANDS, OR CAUSES OF ACTION AND AGREE THAT THIS INSTRUMENT SHALL BE AND REMAIN EFFECTIVE IN ALL RESPECTS NOTWITHSTANDING ANY SUCH
DIFFERENCES OR ADDITIONAL FACTS. EACH RELEASING PARTY UNDERSTANDS, ACKNOWLEDGES AND AGREES THAT THE RELEASE SET FORTH ABOVE MAY BE PLEADED AS A FULL AND COMPLETE DEFENSE AND MAY BE USED AS A BASIS FOR AN INJUNCTION AGAINST ANY ACTION, SUIT OR OTHER
PROCEEDING WHICH MAY BE INSTITUTED, PROSECUTED OR ATTEMPTED IN BREACH OF THE PROVISIONS OF SUCH RELEASE. 
 (b) EACH RELEASING PARTY, ON
BEHALF OF ITSELF AND ITS SUCCESSORS, ASSIGNS, AND OTHER LEGAL REPRESENTATIVES, HEREBY ABSOLUTELY, UNCONDITIONALLY AND IRREVOCABLY, COVENANTS AND AGREES WITH AND IN FAVOR OF EACH RELEASED PARTY THAT IT WILL NOT SUE (AT LAW, IN EQUITY, IN ANY
REGULATORY PROCEEDING OR OTHERWISE) ANY RELEASED PARTY ON THE BASIS OF ANY CLAIM, DEMAND OR CAUSE OF ACTION RELEASED, REMISED AND DISCHARGED BY SUCH RELEASING PARTY PURSUANT 

  
 6 

 
TO THE ABOVE RELEASE. IF ANY RELEASING PARTY OR ANY OF ITS SUCCESSORS, ASSIGNS OR OTHER LEGAL REPRESENTATIVES VIOLATES THE FOREGOING COVENANT, SUCH RELEASING PARTY, FOR ITSELF AND ITS SUCCESSORS,
ASSIGNS AND LEGAL REPRESENTATIVES, AGREES TO PAY, IN ADDITION TO SUCH OTHER DAMAGES AS ANY RELEASED PARTY MAY SUSTAIN AS A RESULT OF SUCH VIOLATION, ALL ATTORNEYS’ FEES AND COSTS INCURRED BY SUCH RELEASED PARTY AS A RESULT OF SUCH VIOLATION.

 (c) EACH RELEASING PARTY REPRESENTS AND WARRANTS THAT THERE ARE NO LIABILITIES, CLAIMS, SUITS, DEBTS, LIENS, LOSSES, CAUSES OF ACTION,
DEMANDS, RIGHTS, DAMAGES OR COSTS, OR EXPENSES OF ANY KIND, CHARACTER OR NATURE WHATSOEVER, KNOWN OR UNKNOWN, FIXED OR CONTINGENT, WHICH SUCH RELEASING PARTY MAY HAVE OR CLAIM TO HAVE AGAINST ANY RELEASED PARTY ARISING UNDER, IN CONNECTION WITH,
AND/OR WITH RESPECT TO THE OBLIGATIONS, THE CREDIT AGREEMENT, THIS AMENDMENT OR ANY OF THE OTHER LOAN DOCUMENTS, AND EACH RELEASING PARTY FURTHER ACKNOWLEDGES THAT, AS OF THE DATE HEREOF, IT DOES NOT HAVE ANY COUNTERCLAIM, SET-OFF, OR DEFENSE
AGAINST ANY OF THE RELEASED PARTIES, EACH OF WHICH SUCH RELEASING PARTY HEREBY EXPRESSLY WAIVES. 
 SECTION 9. Reference to and
Effect on the Loan Documents. (a) Upon the effectiveness of this Amendment, on and after the date hereof each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof” or words of like import
referring to the Credit Agreement, and each reference in the other Loan Documents to “the Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement, shall mean and be a
reference to the Credit Agreement as amended hereby. 
 (b) Except as specifically amended, modified or provided above, the
Credit Agreement, and all other Loan Documents, are and shall continue to be in full force and effect in accordance with their respective terms and are hereby in all respects ratified and confirmed by each Borrower (other than the Released
Borrowers), and each Borrower (other than the Released Borrowers) shall remain fully liable for the payment and performance of all of the Secured Obligations. 

(c) The execution, delivery and effectiveness of this Amendment shall not, except as expressly provided herein, operate as a
waiver of any right, power or remedy of any Lender or the Administrative Agent under any of the Loan Documents, nor constitute a waiver of any provision of any of the Loan Documents. 

(d) This Amendment is a Loan Document in all respects and for all purposes. 

SECTION 10. Further Assurances. Each Borrower agrees that it will, at such Borrower’s expense and upon the request of the
Administrative Agent, duly execute and deliver, or cause to be duly executed and delivered, to the Administrative Agent such further documents and do and cause to be done such further acts as may be necessary or proper in the opinion of the
Administrative Agent to carry out more effectively the provisions and purposes of this Amendment and each of the other Loan Documents. 

  
 7 

 SECTION 11. Costs and Expenses. The Borrowers jointly and severally agree to pay or
reimburse the Administrative Agent on demand for all of its out-of-pocket costs and expenses incurred in connection with this Amendment, any other documents prepared in connection herewith and the transactions contemplated hereby, including, without
limitation, the reasonable fees and disbursements of counsel to the Administrative Agent. 
 SECTION 12. Binding Agreement;
Assignment. This Amendment shall be binding on the parties hereto and their respective successors and assigns; provided, however, that none of the Borrowers may assign or delegate any of its rights or obligations hereunder without
the prior written consent of the Administrative Agent and each Lender. 
 SECTION 13. Execution in Counterparts. This Amendment
may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which taken together shall constitute but one and the
same agreement. Delivery of an executed counterpart of a signature page of this Amendment by facsimile or in electronic (i.e., “pdf” or “tif”) format shall be effective as delivery of a manually executed counterpart of
this Amendment. 
 SECTION 14. Acknowledgment. Each Borrower hereby acknowledges that it has been advised by counsel in the
negotiation, preparation, execution and delivery of this Amendment. 
 SECTION 15. Governing Law. This Amendment shall be
governed by, and construed in accordance with, the laws of the State of Texas. 
 SECTION 16. Time of the Essence. Time is of
the essence of this Amendment and the other Loan Documents. 
 SECTION 17. Survival. All representations and warranties made in
this Amendment or any other Loan Document shall survive the execution and delivery of this Amendment, and no investigation by the Administrative Agent or the Lenders or any closing will affect such representations and warranties or the right of the
Administrative Agent or the Lenders to rely upon them. 
 SECTION 18. Headings. The section headings hereof are inserted for
convenience of reference only and shall in no way alter, amend, define or be used in the construction or interpretation of the text of such section. 

SECTION 19. ENTIRE AGREEMENT. THIS AMENDMENT, THE CREDIT AGREEMENT AND THE OTHER LOAN DOCUMENTS COLLECTIVELY REPRESENT THE FINAL
AGREEMENT AMONG THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NOT UNWRITTEN ORAL AGREEMENTS AMONG THE PARTIES. 

  
 8 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed and delivered by
their proper and duly authorized officers as of the date first above written. 
  

			
	
	ADMINISTRATIVE AGENT:
	
	 SOUTHWEST BANK,
 a Texas
state bank, as Administrative Agent

		
	By:	 	 /s/ Josh Burleson

	Name:	 	Josh Burleson
	Title:	 	Senior Vice President

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	LENDER:
	
	 SOUTHWEST BANK,
 a Texas
state bank, as the sole Lender

		
	By:	 	 /s/ Josh Burleson

	Name:	 	Josh Burleson
	Title:	 	Senior Vice President

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	BORROWERS:
	
	USMD HOLDINGS, INC.
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	IMPEL MANAGEMENT SERVICES, L.L.C.
		
	By:	 	USMD Holdings, Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	IMPEL CONSULTING EXPERTS, L.L.C.
		
	By:	 	Impel Management Services, L.L.C., its sole member
		
	By:	 	USMD Holdings, Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	USMD INC.
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	MAT-RX DEVELOPMENT, L.L.C.
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	MAT-RX FORT WORTH GP, L.L.C.
		
	By:	 	MAT-RX DEVELOPMENT, L.L.C., its sole member
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	USMD OF ARLINGTON GP, L.L.C.
		
	By:	 	MAT-RX DEVELOPMENT, L.L.C., its sole member
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	USGP, LLC
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	US LITHOTRIPSY, L.P.
		
	By:	 	USGP, LLC, its general partner
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	LITHO GP, LLC
		
	By:	 	US Lithotripsy, L.P., its sole member
		
	By:	 	USGP, LLC, its general partner
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	METRO I STONE MANAGEMENT, LTD.
		
	By:	 	Litho GP, LLC, its general partner
		
	By:	 	US Lithotripsy, L.P., its sole member
		
	By:	 	USGP, LLC, its general partner
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	USMD ADMINISTRATIVE SERVICES, L.L.C.
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	USMD DIAGNOSTIC SERVICES, LLC
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	USMD PPM, LLC
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	USMD CANCER TREATMENT CENTERS, L.L.C.
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	USMD CANCER TREATMENT CENTERS GP, L.L.C.
		
	By:	 	USMD Cancer Treatment Centers, L.L.C., its sole member
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	USMD AFFILIATED SERVICES
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	MEDICAL CLINIC OF NORTH TEXAS PLLC
		
	By:	 	USMD Affiliated Services, its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 
			
	UROLOGY ASSOCIATES OF NORTH TEXAS, P.L.L.C.
		
	By:	 	USMD Affiliated Services, its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer
	
	 USMD CTC (MO), LLC,
 a
Missouri limited liability company

		
	By:	 	USMD Cancer Treatment Centers, L.L.C., its sole member
		
	By:	 	USMD Inc., its sole member
		
	By:	 	 /s/ Michael Dooley

	Name:	 	Michael Dooley
	Title:	 	Chief Accounting Officer

  
 Signature Page 

Consent, Waiver and Amendment No. 12 to Credit Agreement 

 ANNEX A 

FORM OF COMPLIANCE CERTIFICATE 
  

	To:	Southwest Bank, 

 as Administrative Agent, 

and the Lenders Parties to the 

Credit Agreement Referred to Below 

This Compliance Certificate is furnished pursuant to that certain Credit Agreement dated as of August 31, 2012 (as amended, restated,
supplemented or otherwise modified from time to time, the “Credit Agreement”) among USMD Holdings, Inc., a Delaware corporation, the other Borrowers party thereto, the Lenders party thereto and Southwest Bank, as Administrative
Agent for the Lenders. Unless otherwise defined herein, capitalized terms used in this Compliance Certificate have the meanings ascribed thereto in the Credit Agreement. 

The undersigned hereby certifies, on its behalf and on behalf of the Borrowers, that: 

1. I am the duly elected
                     of the Borrower Representative. 

2. I have reviewed and am familiar with the contents of this Certificate. 

3. I have reviewed the terms of the Credit Agreement and the other Loan Documents and have made, or have caused to be made under my
supervision, a detailed review of the transactions and condition of each Borrower during the accounting period covered by the financial statements attached hereto as Attachment 1 that are delivered on the date hereof pursuant to
Section 5.01 of the Credit Agreement (the “Financial Statements”). [Except as set forth below], [s]uch review did not disclose, and I have no knowledge of (i) the existence of any condition or event that constitutes a
Default or Event of Default during or at the end of the accounting period covered by the Financial Statements or as of the date of this Certificate or (ii) any change in GAAP or in the application thereof that has occurred since the date of the
audited financial statements referred to in Section 4.01(b) of the Credit Agreement. To the best of my knowledge, each Borrower during the period covered by the Financial Statements has observed or performed all of its covenants and other
agreements, and satisfied every condition contained in the Credit Agreement and the other Loan Documents to which it is a party to be observed, performed or satisfied by it. 

5. Attached hereto as Attachment 2 are the financial data and computations showing (in reasonable detail) compliance by the Borrowers
with the covenants set forth in Sections 6.01, 6.02(c), 6.02(e), 6.02(f), 6.02(h), 6.02(i), 6.02(j), 6.05(e), 6.06(b), 6.06(c)(i), 6.08(h), and 6.08(j) of the Credit Agreement, all of which financial data and computations are true, complete and
correct. 
 6. Attached hereto as Attachment 3 is (i) a description of any change in the jurisdiction of organization or the
name of any Borrower, (ii) a list of all Intellectual Property acquired by any Borrower, (iii) a list of all real property (including material leasehold interests) acquired by any 

 
Borrower, and (iv) a description of each Person that has become a Wholly Owned Subsidiary of Holdings, in each case since the most recent Compliance Certificate was delivered (or in the case
of the first Compliance Certificate so delivered, since the Closing Date). 
 Described below are the exceptions, if any, to paragraph 3 by
listing, in detail, the (i) nature of the condition or event, the period during which it has existed and the action that the Borrowers have taken, are taking, or propose to take with respect to each such condition or event or (ii) the
change in GAAP or the application thereof and the effect of such change on the attached financial statements: 
  

 
  

 
  

 
 The foregoing certifications,
together with the computations set forth in Attachment 2 and the Financial Statements delivered with this Certificate in support hereof, are made and delivered this      day of
            , 201  . 
  

			
	USMD HOLDINGS, INC., as
	Borrower Representative
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 Attachment 1 

to Compliance Certificate 

Financial Statements 

 Attachment 2 

to Compliance Certificate 
 For the
Calendar Month/Fiscal Year ended             ,          (“Statement Date”) 

Compliance with 
 Provisions of
Section 6.01(a) of the Credit Agreement1 
  

	I.	Minimum Fixed Charge Coverage Ratio. 

  

									
	A.	 	EBITDA:	  	
				
		 		  	Net Income for the twelve-month period ending on the Statement Date (the “Subject Period”)	  	$[                    ]
					
		 		  	Plus	  	(without duplication and to the extent reflected as a charge in the statement of such Net Income for the Subject Period):	  	
					
		 		  		  	Tax expense	  	$[                    ]
					
		 		  		  	Interest Expense, amortization or write-off of debt discount and debt issuance costs and commissions, discounts and other fees and charges associated with Indebtedness (including the Loans)	  	$[                    ]
					
		 		  		  	Depreciation and amortization expense	  	$[                    ]
					
		 		  		  	Amortization of intangibles (including, but not limited to, goodwill)	  	$[                    ]
					
		 		  		  	Any extraordinary, unusual or non-recurring non-cash expenses or losses (including, whether or not otherwise includable as a separate item in the statement of such Net Income for such period, non-cash losses on sales of assets
outside of the ordinary course of business)	  	$[                    ]
					
		 		  		  	Any other non-cash charges	  	$[                    ]
					
		 		  		  	Retention that has accrued and not been paid	  	$[                    ]
					
		 		  		  	Accrued and unpaid executive compensation under the Deferred Executive Compensation Plan	  	$[                    ]

 
  

	1 	 To be determined as of the end of each Fiscal Quarter and each Fiscal Year. 

									
		 		  	Minus	  	(to the extent included in the statement of such Net Income for the Subject Period):	  	
					
		 		  		  	Any extraordinary, unusual or non-recurring income or gains (including, whether or not otherwise includable as a separate item in the statement of such Net Income for the Subject Period, gains on the sales of assets outside of the
ordinary course of business)	  	$[                    ]
					
		 		  		  	Any other non-cash income	  	$[                    ]
					
		 		  	Minus:	  		  	
					
		 		  		  	All Retention Payments paid in cash	  	$[                    ]
					
		 		  		  	All cash payments made pursuant to the Deferred Executive Compensation Plan	  	$[                    ]
					
		 		  		  	The amount of all Special Capital Contributions made by Mat-Rx Development, L.L.C. to USMD Arlington pursuant to the USMD Arlington Partnership Agreement during the Subject Period	  	$[                    ]
				
		 		  	EBITDA for Subject Period	  	$[                    ]
			
	B.	 	Fixed Charges:	  	
				
		 		  	Sum of (without duplication):	  	
					
		 		  		  	Interest Expense for the Subject Period	  	$[                    ]
					
		 		  		  	Scheduled payments during the Subject Period on account of principal of Indebtedness (other than Subordinated Debt) of the Borrowers or any of them (including scheduled principal payments in respect of the Term Loans, but excluding
(i) any scheduled payment of principal in respect of Indebtedness of the CTC Entities, the Hospital Entities, or the Lithotripsy Entities, unless such payment is made by a Borrower, and (ii) the payment or prepayment of the Tranche C Term Loans
required by Section 5 of the Amendment No. 4), minus any payments of principal and interest paid by the Borrower with respect to Indebtedness referred to in Section 6.02(k) of the Credit Agreement.	  	$[                    ]
					
		 		  		  	Scheduled payments during the Subject Period on account of principal of Subordinated Debt that are paid in cash	  	$[                    ]

									
		 		  	Fixed Charges for the Subject Period	  	$[                    ]
			
	C.	 	Fixed Charge Coverage Ratio:	  	
					
		 		  	1.	  	All cash dividends and cash distributions, and all redemptions and repurchases of Equity Interests in cash, by any Borrower during the Subject Period (other than (x) dividends or distributions made to a Borrower and (y) the
Deferred Comp Change of Control Payments)	  	$[                    ]
					
		 		  	2.	  	All cash taxes paid by the Borrowers during the Subject Period	  	$[                    ]
					
		 		  	3.	  	Aggregate amount actually paid by the Borrowers during the Subject Period on account of Capital Expenditures (excluding (i) the principal amount of Indebtedness (other than the Loans) incurred in connection with such expenditures
but including payments of principal in respect of any such Indebtedness, (ii) any such expenditures financed with the proceeds of any Reinvestment Deferred Amount, and (iii) the aggregate amount of Capital Expenditures financed with proceeds of any
Revolving Loans, up to a maximum aggregate amount of $1,500,000 in any Fiscal Year starting with Fiscal Year 2015)	  	$[                    ]
					
		 		  	4.	  	Line C.1 plus Line C.2 plus Line C.3	  	$[                    ]
					
		 		  	5.	  	EBITDA minus Line C.4	  	$[                    ]
					
		 		  	6.	  	Fixed Charges	  	$[                    ]
					
		 		  	7.	  	Fixed Charge Coverage Ratio (Line C.5 to C.6)	  	[        :        ]
					
		 		  	8.	  	Fixed Charge Coverage Ratio must be greater than or equal to	  	        :1.00
					
		 		  	9.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no

 Compliance with 

Provisions of Section 6.01(c) of the Credit Agreement2 

 

	II.	Capital Expenditures. 

  

							
	1.	 	Capital Expenditures of the Borrowers for the Fiscal Year ending December 31, 20    	  	 	$[                    ]	  
			
	2.	 	Capital Expenditures must not exceed the following amounts during the following periods:	  			
			
	 	 	 Fiscal Year Ending On
	  	Maximum Capital
Expenditures	 
	 	December 31, 2015	  	$	15,000,000	  
	 	  
 December 31, 2016
	  	$	6,000,000	  
			
	3.	 	The Borrowers are in compliance (circle yes or no)	  	 	yes/no	  

  
  

	2 	To be determined as of the end of each Fiscal Year. 

 Compliance with 

Provisions of Section 6.01(d) of the Credit Agreement3 

 

	III.	Maximum Senior Leverage Ratio. 

  

					
	A.	  	Consolidated Total Indebtedness at Statement Date	  	$[                    ]
			
	B.	  	Outstanding principal of Subordinated Debt at Statement Date	  	$[                    ]
			
	C.	  	Outstanding principal of Convertible Notes at Statement Date	  	$[                    ]
			
	D.	  	Outstanding principal amount of Tranche A Term Loans fully Cash Collateralized	  	$[                    ]
			
	E.	  	Outstanding principal amount of New USMD Arlington Credit Facility	  	$[                    ]
			
	F.	  	Consolidated Senior Indebtedness (Line III.A minus the sum of Lines III.B, III.C and III.D and III.E)	  	$[                    ]
			
	G.	  	EBITDA for the Subject Period (from I.A of this Attachment 2)	  	$[                    ]
			
	H.	  	Senior Leverage Ratio (ratio of Line III.F to Line III.G)	  	        :1.00
			
	I.	  	Senior Leverage Ratio must be less than or equal to	  	1.00 : 1.00
			
	J.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no

  
  

	3 	To be determined as of the end of each Fiscal Quarter and each Fiscal Year. 

 Compliance with provisions of Sections 6.02(c), 6.02(e), 6.02(f), 

6.02(h), 6.02(i), 6.02(j), 6.05(e), 6.06(b), 6.06(c)(i), 6.08(h), and 6.08(j) of the Credit Agreement4 
  

							
	1.	  	Section 6.02(c)	  	
				
		  	A.	  	Guarantee Obligations incurred by the Borrowers (i) in respect of any Indebtedness of any of the Borrowers otherwise permitted by this Section 6.02, (ii) with respect to the CTC Entities, in an aggregate amount, for all such
entities, not to exceed at any time outstanding $2,000,000 in excess of the amounts then owing under the guarantee of existing Indebtedness by CTC Entities identified on Schedule 6.02(d) to the Credit Agreement (provided that, for purposes of the
calculations under this Section 6.02(c), the amounts used as the amounts then owing under the guarantee of existing Indebtedness by CTC Entities identified on Schedule 6.02(d), shall reduce as such guaranteed Indebtedness is paid or reduced [and not
thereafter increase after such reduction] and shall in no event exceed $1,086,715), and (iii) with respect to the Hospital Entities, in an aggregate amount, for all such entities, not to exceed at any time outstanding $3,000,000 in excess of the
amounts then owing under the guarantees of existing Indebtedness by Hospital Entities identified on Schedule 6.02(d) to the Credit Agreement (provided that, for purposes of the calculations under this Section 6.02(c), the amounts used as the amounts
then owing under the guarantees of existing Indebtedness by Hospital Entities identified on Schedule 6.02(d), shall reduce as such guaranteed Indebtedness is paid or reduced [and not thereafter increase after such reduction] and shall in no event
exceed the portion of the Indebtedness guaranteed by Hospital Entities under Schedule 6.02(d), paragraphs 1 and 2)	  	$[                    ]
				
		  	B.	  	Hospital Entities	  	$[                    ]
				
		  	C.	  	CTC Entities	  	$[                    ]
				
		  	D.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	2.	  	Section 6.02(e)	  	
				
		  	A.	  	Indebtedness (including, without limitation, Capital Lease Obligations) secured by Liens permitted by Section 6.03(g) in an aggregate principal amount not to exceed $10,000,000 at any one time outstanding	  	$[                    ]

  
  

	4 	To be determined as of the end of each calendar month (except for Section 6.05(e)). 

							
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	3.	  	Section 6.02(f)	  	
				
		  	A.	  	Permitted Subordinated Debt	  	$[                    ]
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	4.	  		  	Section 6.02(h)
				
		  	A.	  	Additional unsecured Indebtedness of the Borrowers in an aggregate principal amount not to exceed $1,000,000	  	$[                    ]
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	5.	  	Section 6.02(i)	  	
				
		  	A.	  	Guarantee Obligations and/or obligations as a co-obligor with respect to Indebtedness incurred by physicians in the ordinary course of business in connection with the commencement of their employment with a Borrower or any Affiliate
of a Borrower, provided that such Guarantee Obligations shall not exceed $3,000,000 in the aggregate at any time outstanding	  	$[                    ]
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	6.	  	Section 6.02(j)	  	
				
		  	A.	  	Mat-Rx Development, L.L.C. may guarantee the payment of not more than its pro rata share (subject to adjustment) of the principal of and interest the loans outstanding under the Amended and Restated Credit Agreement, dated as of
September 18, 2015, among USMD Arlington, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent for such lenders	  	$[                    ]
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	7.	  	Section 6.05(e)	  	
				
		  	A.	  	Disposition of other property (other than Equity Interests) having a fair market value not to exceed $500,000 in the aggregate for any Fiscal Year, provided that MX Centros de Cancer, de R.L., de C.V., Willowbrook Cancer Treatment
Center, LLC, and Millennium Lithotripsy, LP may be dissolved	  	$[                    ]5
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no

  
  

	5 	For the Compliance Certificate delivered with the financial statements required by Section 5.01(a), insert actual amount for the Fiscal Year most recently ended. 

							
	8.	  	Section 6.06(b)	  	
				
		  	A.	  	Restricted Payments by the Borrowers to Holdings to permit Holdings to purchase Holdings’ common stock or common stock options from present or former officers or employees of any Borrower upon the death, disability or
termination of employment of such officer or employee, provided, that the aggregate amount of payments under this clause after the Closing Date (net of any proceeds received by Holdings after the Closing Date in connection with resales of any
common stock or common stock options so purchased) shall not exceed $250,000	  	$[                    ]
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	9.	  	Section 6.06(c)(i)	  	
				
		  	A.	  	Scheduled payments of principal and interest on Subordinated Debt to Dr. House and Dr. Thompson (and their permitted successors and assigns) made during the Subject Period	  	$[                    ]
				
		  	B.	  	Scheduled payments of principal and interest on the Convertible Notes made during the Subject Period	  	$[                    ]
				
		  	C.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	10.	  	Section 6.08(h)	  	
				
		  	A.	  	Investments after the Closing Date by the Borrowers in Subsidiaries that are not Wholly Owned Subsidiaries, provided that the aggregate amount (valued at cost) of such Investments made after the Closing Date shall not exceed
$1,000,000 per Fiscal Year	  	$[                    ]6
				
		  	B.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no
			
	11.	  	Section 6.08(j)	  	
				
		  	A.	  	The total cash and non-cash consideration for Acquisitions pursuant to Section 6.08(j) shall not exceed during any Fiscal Year (1) in the case of cash consideration, $1,000,000, and (2) in the case of non-cash consideration,
$5,000,000; provided that the non-cash consideration paid by or on behalf of any Borrower in connection with any Acquisition shall be limited to Equity Interests in Holdings	  	

  
  

	6 	For the Compliance Certificate delivered with the financial statements required by Section 5.01(a), insert actual amount for the Fiscal Year most recently ended. Otherwise, insert the year to date amount as of the last
day of the Fiscal Quarter most recently ended. 

							
		  	B.	  	Total cash consideration	  	$[                    ]7
				
		  	C.	  	Total non-cash consideration	  	$[                    ]8
				
		  	D.	  	The Borrowers are in compliance (circle yes or no)	  	yes/no

  
  

	7 	For the Compliance Certificate delivered with the financial statements required by Section 5.01(a), insert actual amount for the Fiscal Year most recently ended. Otherwise, insert the year to date amount as of the last
day of the Fiscal Quarter most recently ended. 

	8 	For the Compliance Certificate delivered with the financial statements required by Section 5.01(a), insert actual amount for the Fiscal Year most recently ended. Otherwise, insert the year to date amount as of the last
day of the Fiscal Quarter most recently ended. 

 Attachment 3 

to Compliance Certificate 

Description of Change in 

Jurisdiction of Organization, Name, any Intellectual Property Acquired, EtcExhibit 10.1

 

FORM OF EXECUTIVE EXCISE TAX AND WAIVER AGREEMENT

 

THIS AGREEMENT, effective as of [DATE], is made by and between CF Industries Holdings, Inc., a Delaware corporation (the “Company”), and [EXECUTIVE] (the “Executive”).

 

WHEREAS, the Company has entered into that certain Combination Agreement by and among the Company, Darwin Holdings Limited, Beagle Merger Company LLC, OCI N.V. and certain other parties, dated August 6, 2015, as subsequently amended and as may be further amended (the “Combination Agreement”);

 

WHEREAS, the Executive and the Company are parties to a Change in Control Severance Agreement, as amended, as applicable (the “Change in Control Agreement”);

 

WHEREAS, in connection with the consummation of the transactions contemplated under the Combination Agreement (the “Closing”), it is contemplated that certain stock-based compensation held by the Executive will become subject to an excise tax under Section 4985 (“Section 4985”) of the Internal Revenue Code of 1986, as amended (the “Code”), as a result of the Closing;

 

WHEREAS, the Company has determined it is in the best interests of the Company to provide to the Executive a tax gross-up payment such that, after payment by the Executive of the excise tax under Section 4985 of the Code, the Executive will receive the net after-tax benefit that the Executive would have received had the excise tax not been imposed;

 

WHEREAS, in exchange for the Gross-Up Payment (as defined below), the Company and the Executive have agreed to the terms set forth herein;

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Company and the Executive hereby agree as follows:

 

1.                                      Gross-Up Payment.  In the event any amounts payable to the Executive with respect to stock-based compensation (within the meaning of Section 4985 of the Code) become subject to an excise tax under Section 4985 of the Code, the Company shall pay to the Executive an excise tax gross-up payment such that, after payment by the Executive of all taxes, including any excise tax imposed upon the gross-up payment, the Executive will receive the net after-tax benefit the Executive would have received had the excise tax not been imposed under Section 4985 of the Code (the “Gross-up Payment”).

 

2.                                      Modification to Outstanding Equity Awards.  In exchange for payment by the Company of the Gross-Up Payment, the Executive acknowledges and agrees that notwithstanding anything to the contrary in the Combination Agreement or under any equity and incentive plan of the Company (or any award agreements thereunder) or any employment, severance, change in control or similar agreement between the Company and the Executive, and notwithstanding that the Closing would constitute a “Change in Control” under the equity and incentive plans of the Company, the Executive’s stock options, restricted stock awards, restricted

 

 

stock units and performance restricted stock units will not vest in whole or in part upon, or in connection with, the Closing.  The Executive’s stock options, restricted stock awards, restricted stock units and performance restricted stock units outstanding immediately prior to the Closing will instead be converted upon the Closing into stock options, restricted stock awards, restricted stock units and performance restricted stock units, respectively, covering shares of the surviving holding company (as provided under the Combination Agreement), with the number of stock options, restricted stock awards, restricted stock units and performance restricted stock units adjusted, in each case, to preserve the value of the applicable award, and will otherwise be subject to the terms and conditions set forth in the applicable equity and incentive plan of the Company and the applicable award agreement pursuant to which the award was granted, including the vesting terms; provided, that, in the event the Executive’s employment is terminated by the Company without Cause (as defined below) or by the Executive for Good Reason (as defined below) within 24 months following the Closing, the outstanding stock options, restricted stock awards, restricted stock units and performance restricted stock units held by the Executive at the time of such termination will vest in full, and, with respect to restricted stock awards, restricted stock units and performance restricted stock units, the underlying shares delivered, upon such termination date.

 

3.                                      Modification to Change in Control Agreement.  The Executive acknowledges and agrees that for purposes of the Executive’s entitlement to severance benefits under Section 6 of the Change in Control Agreement, solely to the extent the Closing is the event constituting a “Change in Control” under the Change in Control Agreement, the term “Good Reason” shall have the meaning set forth in this Agreement, which meaning shall supersede in its entirety the definition given to such term in the Change in Control Agreement.

 

4.                                      Definitions.  For purposes of this Agreement, the following terms shall have the meanings ascribed to them below:

 

4.1                               “Board” shall mean the board of directors of the Company.

 

4.2                               “Cause” shall have the meaning ascribed to such term in any individual employment, severance or other agreement with the Company to which the Executive is a party or, if the Executive is not party to such an agreement, “Cause” shall mean (i) dishonesty in the performance of the Executive’s duties or (ii) Executive’s malfeasance or misconduct in connection with the Executive’s duties or any act or omission which is injurious to the Company or its Subsidiaries or affiliates, monetarily or otherwise, each as determined by the Committee in its sole discretion.

 

4.3                               “Good Reason” shall mean termination by the Executive of the Executive’s employment by reason of any of the following (without the Executive’s express written consent which specifically references this Agreement):  (i)  the assignment to Executive of any duties inconsistent with the Executive’s status as an executive officer of the Company or a substantial adverse alteration in the nature or status of the Executive’s responsibilities from those in effect immediately prior to the Change in Control; (ii) a reduction by the Company in the Executive’s annual base salary and annual target bonus, as in effect on the date hereof or as the same may be increased from time to time, by an amount more than 10% in the aggregate; or (iii)  the relocation of the Executive’s principal place of employment to a location more than 35 miles from the Executive’s principal place of employment immediately prior to the Change in Control

 

 

or the Company’s requiring the Executive to be based anywhere other than such principal place of employment (or permitted relocation thereof) except for required travel on the Company’s business to an extent substantially consistent with the business travel obligations as of immediately prior to a Change in Control.  The Executive’s continued employment shall not constitute consent to, or a waiver of rights with respect to, any act or failure to act constituting Good Reason hereunder, provided that, in order for Good Reason to exist hereunder, the Executive must provide notice to the Company of the existence of the condition described in clauses (i) through (iii) above within 90 days of the initial existence of the condition (or, if later, within 90 days of the Executive becoming aware of such condition), and the Company must have failed to cure such condition within 30 days of the receipt of such notice.

 

5.                                      Agreement Contingent on Closing.  Notwithstanding anything to the contrary in this Agreement or otherwise, the effectiveness of this Agreement, and the terms set forth herein, shall be subject to and contingent upon the occurrence of the Closing.  In the event that the Closing does not occur, this Agreement shall be void and have no force or effect.

 

6.                                      Notices.  For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and shall be deemed to have been duly given when delivered or mailed by United States registered mail, return receipt requested, postage prepaid, addressed, if to the Executive, to the address inserted below the Executive’s signature on the final page hereof and, if to the Company, to the address set forth below, or to such other address as either party may have furnished to the other in writing in accordance herewith, except that notice of change of address shall be effective only upon actual receipt:

 

To the Company:

 

CF Industries Holdings, Inc.

4 Parkway North, Suite 400

Deerfield, Illinois 60015-2590

 

Attention: Senior Vice President, Human Resources

 

7.                                      Miscellaneous.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Executive and such officer as may be specifically designated by the Board.  No waiver by either party hereto at any time of any breach by the other party hereto of, or of any lack of compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.

 

8.                                      Validity.  The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.

 

 

9.                                      Counterparts.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.

 

10.                               Section 409A.   The intent of the Executive and the Company is that payments and benefits under this Agreement be exempt from, or comply with, Section 409A of the Code and accordingly, to the maximum extent permitted, this Agreement shall be interpreted and administered to be in accordance therewith. Each payment under this Agreement shall be construed as a separate identified payment for purposes of Section 409A of the Code, and any payments described in this Agreement that are due within the “short term deferral period” as defined in Section 409A of the Code shall not be treated as deferred compensation unless applicable law requires otherwise. Notwithstanding anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code, (i) the Executive shall not be considered to have terminated employment for purposes of this Agreement and no payments shall be due to the Executive under this Agreement that are payable upon the Executive’s termination of employment until the Executive would be considered to have incurred a “separation from service” within the meaning of Section 409A of the Code and (ii) amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Agreement during the six-month period immediately following the Executive’s separation from service shall instead be paid on the first business day after the date that is six months following the Executive’s separation from service (or, if earlier, the Executive’s death).

 

11.                               Voluntary Execution.   The Executive acknowledges and agrees that this Agreement is executed voluntarily and that Executive (a) has read this Agreement; (b) understands the terms and consequences of this Agreement; and (c) is fully aware of the legal and binding effect of this Agreement.

 

IN WITNESS WHEREOF, the parties have executed this Agreement, effective as of the date first set forth above.

 

 

	
 
    	
 
    	
CF INDUSTRIES   HOLDINGS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
By:
    	
 
    
	
 
    	
 
    	
 
    	
Name:
    
	
 
    	
 
    	
 
    	
Title:
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
EXECUTIVE
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
[          ]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]